Nevakar

Executive Summary

Nevakar Inc. is a privately held biopharmaceutical company headquartered in Bridgewater, New Jersey, founded in 2015. The company is dedicated to developing innovative ophthalmic products and advanced drug delivery technologies to address unmet needs in eye care. Nevakar operates through two distinct subsidiaries: Vyluma, which focuses on refractive error treatments such as myopia progression, and Nevakar Injectables, which develops other ophthalmic solutions. The company's pipeline leverages proprietary delivery platforms to enhance efficacy, safety, and patient compliance. While specific financial details are undisclosed, Nevakar has attracted interest for its novel approach to ocular therapeutics and its potential to capture significant market share in the growing ophthalmic sector. Nevakar's most advanced candidate is NVK-002, a low-dose atropine formulation for myopia control in children, developed under Vyluma. The company has completed pivotal clinical trials and is preparing for regulatory submissions in key markets. Additional pipeline assets target dry eye disease, presbyopia, and other anterior segment conditions. Nevakar's strengths lie in its differentiated formulations and strategic partnerships for commercialization. The company is expected to reach critical inflection points over the next 12–24 months, with potential FDA approvals and label expansions driving value. However, as a private entity, visibility into financing and valuation remains limited. Overall, Nevakar represents a compelling opportunity in ophthalmic innovation with near-term catalysts.

Upcoming Catalysts (preview)

• Q2 2026NDA submission for NVK-002 in pediatric myopia80% success
• Q4 2026Phase 3 data readout for dry eye disease candidate60% success
• Q1 2027Strategic partnership for commercialization in ex-US markets70% success